About LUCENTIS

LUCENTIS is a prescription medicine used to treat certain eye conditions, including age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion. It contains the active ingredient RANIBIZUMAB, which is a recombinant humanized monoclonal antibody fragment designed for intraocular use. LUCENTIS is administered via intravitreal injection to help reduce vision loss and slow disease progression.

Key Benefits & Uses

Treatment of neovascular (wet) age-related macular degeneration to reduce vision loss
Management of diabetic macular edema to improve vision
Treatment of macular edema following retinal vein occlusion to reduce vision loss

Active Ingredient & Action

RANIBIZUMAB, the active ingredient in LUCENTIS, works by binding to and inhibiting vascular endothelial growth factor A (VEGF-A), a protein that can cause abnormal blood vessel growth and leakage in the eye. By blocking VEGF-A, RANIBIZUMAB reduces the formation of new, fragile blood vessels and minimizes leakage from existing vessels, thereby reducing vision loss and slowing disease progression.

Important Notes

As with any medication, it is essential to follow the dosage and administration instructions provided by your healthcare provider. LUCENTIS should only be administered by a qualified healthcare professional. Patients should be monitored for potential side effects, including eye pain, redness, or increased pressure. It is crucial to attend all scheduled follow-up appointments to ensure the safe and effective use of LUCENTIS.